CUSUMIN组合:用于I期癌症药物组合试验的累积总量间隔设计
Tomoyoshi Hatayama1, Seiichi Yasui2
1Statistics and Decision Sciences Japan, Janssen Pharmaceutical K.K, Tokyo, Japan.
Pharmaceutical statistics
|April 16, 2025
概括
本研究介绍了CUSUMIN,这是一种用于I期癌症试验的新设计,可以提高药物组合研究的安全性. 在保持最大耐受剂量选择性能的同时,CUSUMIN提供了更好的过量控制.
科学领域:
- 在瘤学瘤学.
- 生物统计学 生物统计学
- 临床试验设计 临床试验设计
背景情况:
- 像贝叶斯最佳间隔 (BOIN) 这样的模型辅助设计在I期癌症研究中提供了简单性和良好的性能.
- 药物组合在精密医学中至关重要,但由于复杂的毒性概况,对最大耐受剂量 (MTD) 识别构成挑战.
- 现有的药物组合模型辅助设计,如BOIN和Keyboard,具有类似的操作特性,需要进一步研究.
研究的目的:
- 为癌症第一阶段剂量组合研究开发一种新,简单和高性能设计.
- 改进现有的模型辅助设计,特别是针对组合治疗试验中的过量控制和MTD选择.
- 扩展单剂研究的累积和间隔设计 (CUSUMIN) 到药物组合的复杂设置.
主要方法:
- 扩展累积和间隔设计 (CUSUMIN) 方法,最初是为单剂剂量确定而开发的.
- 应用统计质量控制原则来增强剂量检测算法.
- 对CUSUMIN与现有的模型辅助设计进行比较,包括BOIN,用于I期药物组合试验.
主要成果:
- 与BOIN和其他模型辅助设计相比,CUSUMIN设计在控制过量剂量率方面表现出卓越的性能.
- 在确定药物组合的最大耐受剂量 (MTD) 方面,CUSUMIN保持了相似的性能.
- 扩展的CUSUMIN设计在I期组合研究中提供了更安全的患者分配策略.
结论:
- CUSUMIN设计为I期癌症剂量组合研究提供了更安全,更有效的替代方案.
- 这种新的方法通过降低过量剂量率来提高患者的安全性,同时确保准确的MTD识别.
- CUSUMIN代表了瘤学组合疗法模型辅助试验设计的重大进展.
更多相关视频
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
10.8K
09:19Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
8.2K
相关概念视频
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
01:21Cancer Survival Analysis
303
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
303
01:20Comparing the Survival Analysis of Two or More Groups
90
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
90
01:24Kaplan-Meier Approach
57
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
57
01:12Hazard Ratio
71
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
71
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
140
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
140